BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Clinical & Translational Sciences//NONSGML Events//EN
CALSCALE:GREGORIAN
X-ORIGINAL-URL:https://icts.wustl.edu/events/
X-WR-CALDESC:Clinical & Translational Sciences - Events
BEGIN:VEVENT
UID:20240408T1640Z-1712594415.1957-EO-46348-1@172.23.128.18
STATUS:CONFIRMED
DTSTAMP:20260529T165552Z
CREATED:20240408T163416Z
LAST-MODIFIED:20240408T163416Z
DTSTART;TZID=America/Chicago:20240410T123000
DTEND;TZID=America/Chicago:20240410T133000
SUMMARY: Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndr
 ome
DESCRIPTION: Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Inte
 rim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome CAMBRIDGE
 \, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals\, Inc. (Nasdaq: AMLX) (“Amy
 lyx” or the “Company”) today announced the Company will host a virtual webc
 ast with management and Fumihiko Urano\, MD\, PhD\, Principal Investigator 
 of the HELIOS clinical trial and […]
X-ALT-DESC;FMTTYPE=text/html: <h5 class="epi-fontLg bwalignc"><em><b>Amylyx
  Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase
  2 HELIOS Study of AMX0035 in Wolfram Syndrome</b></em></h5><p>CAMBRIDGE\, 
 Mass.--(<a href="https://www.businesswire.com/" rel="nofollow">BUSINESS WIR
 E</a>)--Amylyx Pharmaceuticals\, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Comp
 any”) today announced the Company will host a virtual webcast with manageme
 nt and Fumihiko Urano\, MD\, PhD\, Principal Investigator of the HELIOS cli
 nical trial and the Samuel E. Schechter Professor of Medicine in the Divisi
 on of Endocrinology\, Metabolism & Lipid Research at Washington University 
 School of Medicine in St. Louis to discuss interim data from HELIOS\, a Pha
 se 2 trial of AMX0035 for the treatment of Wolfram syndrome on April 10\, 2
 024 at 1:30pm ET.</p><p>A live webcast of the presentation can be accessed 
 under “Events and Presentations” in the Investor section of the <a href="ht
 tps://investors.amylyx.com/news-events/events" target="_blank" rel="noopene
 r">Company’s website</a>\, and will be available for replay for 90 days fol
 lowing the event.</p><p><a href="https://investors.amylyx.com/events/event-
 details/amylyx-pharmaceuticals-phase-2-helios-interim-data-wolfram-syndrome
 -investor" target="_blank" rel="noopener"><strong>Learn more.</strong></a><
 /p>
ORGANIZER;CN="McKinzie":MAILTO:tolliver.m@wustl.edu
URL;VALUE=URI:https://icts.wustl.edu/events/event/interim-data-from-phase-2
 -helios-study-of-amx0035-in-wolfram-syndrome/
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
DTSTART:20240310T080000
TZNAME:CDT
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR